Ivermectin and Artemisinin (@triplecrown777)

One modern review reconstructing the Ayurvedic model describes something roughly like: Shotha → Granthi → Arbuda or: persistent inflammation → localized abnormal tissue/glandular change → established tumor-like growth. The authors specifically compare the ancient emphasis on Shotha with today's understanding that chronic inflammation and the inflammatory tumor microenvironment can participate in carcinogenesis. PubMed Central (PMC) That doesn't mean the ancients understood NF-κB, LPS, TLR4 or microbiome signaling. They didn't. But they appear to have recognized the clinical pattern of a chronic disturbed state preceding abnormal tissue growth. And that overlaps conceptually with several things we have recently been investigating. 1. Gut disturbance / metabolism Ayurvedic cancer interpretations frequently involve disturbed digestion/metabolism and abnormal tissue formation. Modern Ayurvedic researchers describe this using agni and dhatu-agni—essentially their conceptual framework for digestion and tissue metabolism. PubMed Central (PMC) That's interesting beside our Haritaki/Triphala investigation because we were specifically looking at: microbiome → bacterial metabolites/LPS/flagellin → inflammation → insulin/metabolic signaling → pancreatic/immune effects. I would not equate agni with the microbiome—that would be historically unjustified—but there is a notable systems-level resemblance: intestinal function was considered upstream of systemic disease. A review discussing classical approaches to Granthi/Arbuda specifically mentions Pathya — Terminalia chebula, which is Haritaki, in the context of historical cancer-like conditions. PubMed Central (PMC) That does not establish Haritaki as a cancer treatment. But it gives us a historical reason to investigate it rather than assuming the connection was invented recently.